William D. O’Riordan, MD, FACEP, chief medical officer, eStudySite, explains how iclaprim has a unique mechanism of action, making it a unique antibiotic to treat acute bacterial skin and skin structure infections. Dr. O’Riordan explains how dihydrofolate reductase interferes with an enzyme that is involved with the bacterial cell and essentially “does away” with it.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
We break down our top HIV news stories of 2017. Did you read them all?
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512